The Big Idea
How psyched would you be if you went to your healthcare provider and they said the following:
“I can make a health optimization recommendation for you, informed not only by the latest clinical trials, but also by local and regional data about like...
Read More
Crista continues to believe this stock is greatly undervalued.
Read More
Profit taking finally set in earlier this week, though this morning’s jobs-inspired pop has erased the losses for the major indexes.
Read More
From Cabot Top Ten Trader
We’re leaning toward the view that the short-term could continue to be choppy and challenging, with some news-driven moves and possibly a few names breaking down. But beyond that, the vast majority of evidence is bullish, so we are For...
Read More
A Normal Breather
As the market pushed sharply higher following its early-October low (10% or so in the S&P 500, 12%-plus in the Nasdaq), rising seven out of eight weeks, the worries of the world (trade wars, slowing economic growth, even impeachment) were slowly As...
Read More
This portfolio stock shares are down 7% as investors worry about a potential pharmaceutical competitor.
Read More
With interest rates on the decline again, stocks are the best place to find income. Here are 5 good stocks with high yields for low-interest-rate climate.
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Our second recommendation is profit-taking due to a buyout.
Read More
With the year coming to an end, now is the time to sell your losing stocks. It should make for a much healthier portfolio in 2020.
Read More
Want to invest in the stocks the big hedge funds are buying in real time? Here's how to do it. But beware: hedge funds get it wrong sometimes too!
Read More
Not a lot has changed since last week’s issue—overall, the cannabis sector remains in a correction—but there are a few stocks worthy of an update.
Read More
This has been a good year for the market. With only weeks left in 2019, the S&P 500 is more than 23% higher for the year. Some of that is the undoing of the overselling at the end of last year. But the has...
Read More
Short-term, the market remains under pressure, buffeted by the selling of investors scared by the prospects of an extended tariff war, but long-term, the trend remains up, so we still see the current weakness as a normal correction.
Read More
December: Time for a Portfolio Shake-Up
Here we are in December, an interesting time in the stock market, as excessive price movements culminate, often reversing course in January. On the bullish side, you may have owned stocks that rose an abnormal amount, all year We...
Read More
As we wrote a week and a half ago, there’s no Top Ten issue today—one of our two weeks off (50 issues a year). But we don’t want to be too out of touch, which is why we’re sending this brief update today, on...
Read More
*** NEW ADVISORY SERVICE ***
We are pleased to announce that on Tuesday, December 10 we will launch Cabot Profit Booster. This new weekly advisory will feature the experience and skill of two veteran Cabot analysts – Mike Cintolo and Jacob Mintz. Each Tuesday Jacob...
Read More
*** NEW ADVISORY SERVICE ***
We are pleased to announce that on Tuesday, December 10 we will launch Cabot Profit Booster. This new weekly advisory will feature the experience and skill of two veteran Cabot analysts – Mike Cintolo and Jacob Mintz. Each Tuesday Jacob...
Read More
Remain bullish. The market and leading stocks continue to act well, and while a pullback, shakeout or some other potholes could occur in the short-term, the odds continue to favor higher prices over time.
Read More
The Smart Money is Moving In
It’s common knowledge among experienced investors that the price of a company’s stock, at any one time, is imperfectly related to the company’s actual value.
Other factors that affect the price include estimates of the company’s future revenues, earnings profit...
Read More
